Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients
This study has been completed.
Staten Island University Hospital
Information provided by (Responsible Party):
Suzanne El-Sayegh, North Shore Long Island Jewish Health System
First received: May 27, 2011
Last updated: May 14, 2013
Last verified: May 2013
The primary objective of the study is to determine the prevalence of aspirin resistance in chronic kidney disease patients. The secondary objectives are to determine possible risk factors contributing to aspirin resistance in this population.
||Observational Model: Case Control
Time Perspective: Cross-Sectional
||Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients
Primary Outcome Measures:
Biospecimen Retention: Samples Without DNA
Secondary Outcome Measures:
- risk factors contributing to aspirin resistance in this population. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||March 2012 (Final data collection date for primary outcome measure)
A cross-sectional of "aspirin resistance in hemodialysis patients" previously done in our institution showed that 23/66 (34.7%) hemodialysis patients were aspirin resistant. In a recent systematic review, renal impairment was associated with aspirin resistance . This association was seen in only two out of the twenty studies used in this meta-analysis . Both these studies are from the same center with a predominant Asian population. In this study we will try to evaluate the prevalence of aspirin resistance in CKD patient without being limited to a specific ethnicity.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients presenting to the nephrology clinic at SIUH and the nephrology clinic at Staten Island rehab and the admitted patients who give consent.
- Patients with known structural kidney disease as evident by history or by urinalysis and CKD stage III or IV determined by MDRD formula and who are taking aspirin.
- Younger than 18 years of age.
- Bleeding disorder or myeloproliferative disorders.
- Thrombocytopenia with platelets < 100.000.
- Acute hemorrhagic disease.
- A recent history of receipt of platelet glycoprotein IIb/IIIa blockers.
- Liver disease as evident by abnormal liver function and total bilirubin > 2mg/dl.
- use of anticoagulation.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01364779
|staten island University Hospital nephrology clinic
|Staten Island, New York, United States, 10305 |
North Shore Long Island Jewish Health System
Staten Island University Hospital
||Suzanne El_Sayegh, MD
||Staten Island University Hospital
No publications provided
||Suzanne El-Sayegh, Nephrology Attending, Assoc. Chair of Medicine, North Shore Long Island Jewish Health System
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 27, 2011
||May 14, 2013
||United States: Institutional Review Board
Keywords provided by North Shore Long Island Jewish Health System:
Chronic kidney disease
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 23, 2013
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Anti-Inflammatory Agents, Non-Steroidal
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Central Nervous System Agents